and that targeting it — including through personalized approaches — may be a treatment pathway,” Heather Snyder, senior ...

A new therapy may delay Alzheimer's disease progression by years, according to a study by researchers at Texas A&M University ...

Researchers at Monash University are conducting clinical trials of a drug that promises to be a game-changer for sufferers of ...

AbbVie (ABBV) announced Monday that it is buying Aliada Therapeutics for $1.4 billion. The deal includes Aliada’s lead drug ...

The drug works by essentially forcing our cells to "spit out" dangerous protein clumps involved in Alzheimer's.

There is a lot of outrage that the new Alzheimer’s drug donanemab is being refused on the NHS. But there are good reasons for ...

A change in the dosing regimen of Eli Lilly’s Alzheimer’s drug Kisunla resulted in a lower rate of brain swelling among ...

The results were pretty astounding: Patients who used Ozempic had a whopping 70% lower risk of Alzheimer's than patients who ...

Opens in a new tab or window Share on X ... bepranemab missed its primary cognitive endpoint in a phase II trial of prodromal ...

A significant number of participants from the INVOKE-2 trial have opted to continue in the long-term extension study, suggesting positive patient sentiment toward the treatment. The baseline patient ...

Commenting for Medscape Medical News, Reisa Sperling, MD, professor of neurology, Harvard Medical School, and director, ...

Two new laws spearheaded by Sen. Susan Collins – signed into law on Oct. 1 – will continue to infuse federal funding into ...